user avatar
Mohamed A. Alfaleh
@Moalfaleh
Biotech and Biopharmaceuticals Expert..@mimgov
Riyadh
linkedin.com/in/mohamedalfa…
Joined December 2015
859
Following
1,766
Followers
  • Pinned
    user avatar
    Mohamed A. Alfaleh
    @Moalfaleh
    Dec 12, 2023
    Our new paper is out @AntibodyT “ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants: A quick therapeutic option for current and future coronaviruses outbreaks” Thanks @Anwar_Hashem et al @VIU_kfmrc. Outstanding effort..
    Generation of soluble recombinant human ACE2-Fc and DPP4-Fc protein as decoy receptors to SARS-CoV-2 and MERS-CoV, respectively. Recombinant human ACE2-Fc and DPP4-Fc proteins were generated by fusing the C terminus of the human ACE2 and DPP4 extracellular domains to a human IgG Fc domain as coronaviruses inhibitors.
    ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants: a quick therapeutic...
    From academic.oup.com
    8.2K
  • user avatar
    Mohamed A. Alfaleh
    @Moalfaleh
    Aug 20, 2020
    اخيراً نجح الكلونينق (cloning) وتم التأكد من البلازمد والان إنتاج اول جسم مضاد بشري احادي النسيلة لفيروس #كورونا_المستجد #كوفيد_١٩ في وحدة اللقاحات والعلاجات المناعية @kfmrc_official @Faculty_Med_KAU @KAUWEB @kau_media @KAUPharmacy
  • user avatar
    Mohamed A. Alfaleh
    @Moalfaleh
    Apr 10, 2020
    Battling
  • user avatar
    Mohamed A. Alfaleh
    @Moalfaleh
    Jan 27, 2021
    Antibodies..
  • user avatar
    Mohamed A. Alfaleh
    @Moalfaleh
    Nov 6, 2019
    Working every day for 11 hrs..I don’t have to do it..But I want to do it.. #ScienceMatters
  • user avatar
    Mohamed A. Alfaleh
    @Moalfaleh
    Dec 12, 2021
    Biologics purification..
  • user avatar
    Mohamed A. Alfaleh
    @Moalfaleh
    Nov 23, 2021
    Upgraded bench.. #mAbs
  • user avatar
    Mohamed A. Alfaleh
    @Moalfaleh
    Mar 28, 2022
    Walking into the lab after my 1st mAbs paper got accepted 👏🏻👏🏻
    00:00
  • user avatar
    Mohamed A. Alfaleh
    @Moalfaleh
    Apr 5, 2022
    Our review which summarizes different evolution strategies that helped generate several modified ACE2-Fc variants as promising anti-SARS-CoV-2 candidates. “David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors”.
    Journal cover image for mAbs
    David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors
    From tandfonline.com
  • user avatar
    Mohamed A. Alfaleh
    @Moalfaleh
    Aug 28, 2020
    Our recent review @FrontImmunol. A methodological overview on #antibody phage display libraries and a detailed description of the isolated antibodies as well as their clinical testing. doi.org/10.3389/fimmu.…
  • user avatar
    Mohamed A. Alfaleh
    @Moalfaleh
    Oct 1, 2023
    نتمنى للبرنامج الاستمرارية وللملتحقين التوفيق انشالله.. نشكر @saudivax @kauweb @kfmrc_official لدعمهم اللامحدود لانجاح البرنامج
    user avatar
    قناة الإخبارية
    @alekhbariyatv
    Oct 1, 2023
    فيديو | أستاذ التقنية الحيوية المشارك د. محمد الفالح: الفئات المستهدفة للبرنامج التدريبي لتصنيع الأدوية البيولوجية خريجي وخريجات الكليات الصحية والعلوم #النشرة_الأولى #الإخبارية
    00:00
    16K
  • user avatar
    Mohamed A. Alfaleh
    @Moalfaleh
    Dec 22, 2023
    Gutted that I am moving out of @kauweb, where I have spent more time than my own house during the past five and a half years.. Still, it's worthwhile.. I only tried to advance my research career and to help my colleagues and students—who became my 2nd family—as we had similar
    10K
  • user avatar
    Mohamed A. Alfaleh
    @Moalfaleh
    Feb 22, 2022
    Mars look-alike
  • user avatar
    Mohamed A. Alfaleh
    @Moalfaleh
    Oct 25, 2017
    بحثنا الجديد: إستخدام بكتيريا محملة بالدواء و محاطة بالأجسام المضادة لإستهداف الخلايا السرطانية فقط dx.plos.org/10.1371/journa…